Form 4 for UTHR UNITED THERAPEUTICS Corp
Accepted 2026-04-30 16:30:55 ET · period of report 2026-04-29 · accession 0001106578-26-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-30 16:30 | 2026-04-29 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $146.03 | +9,500 | 50.0K | +23% | +$1.39M |
| DMT | 2026-04-30 16:30 | 2026-04-29 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | S - Sale+OE | $571.22 | -9,500 | 40.5K | -19% | -$5.43M |
| DT | 2026-04-30 16:30 | 2026-04-29 | UTHR | ROTHBLATT MARTINE A | COB, CEO, Dir | M - OptEx | $0.00 | -9,500 | 91.3K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-29 | M | A | 9,500 | $146.03 | 50,013 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |
| 2 | Common | Common Stock | 2026-04-29 | S | D | 8 | $565.27 | 50,005 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F2) This transaction was executed in multiple trades at prices ranging from $565.10 to $565.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-04-29 | S | D | 32 | $566.34 | 49,973 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $566.15 to $567.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2026-04-29 | S | D | 135 | $567.72 | 49,838 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $567.39 to $568.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Common | Common Stock | 2026-04-29 | S | D | 322 | $568.98 | 49,516 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F5) This transaction was executed in multiple trades at prices ranging from $568.405 to $569.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 6 | Common | Common Stock | 2026-04-29 | S | D | 2,674 | $570.02 | 46,842 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F6) This transaction was executed in multiple trades at prices ranging from $569.455 to $570.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Common | Common Stock | 2026-04-29 | S | D | 2,432 | $570.87 | 44,410 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F7) This transaction was executed in multiple trades at prices ranging from $570.47 to $571.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 8 | Common | Common Stock | 2026-04-29 | S | D | 1,786 | $572.06 | 42,624 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F8) This transaction was executed in multiple trades at prices ranging from $571.47 to $572.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Common | Common Stock | 2026-04-29 | S | D | 1,654 | $572.89 | 40,970 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F9) This transaction was executed in multiple trades at prices ranging from $572.47 to $573.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 10 | Common | Common Stock | 2026-04-29 | S | D | 457 | $573.89 | 40,513 | D | — | — | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. (F10) This transaction was executed in multiple trades at prices ranging from $573.65 to $574.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 11 | Derivative | Stock Option | 2026-04-29 | M | D | 9,500 | $0.00 | 91,288 | D | $146.03 · 2020-03-15 to 2027-03-15 | 9,500 Common Stock | (F1) This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. |